Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677 sales@csnpharm.com    

NAMPT

NAMPT

Cat. No. Product Name CAS No. Information
CSN16533 STF-118804   894187-61-2 STF-118804 is a highly specific and potent NAMPT inhibitor with IC50 values of 3-6 nM
CSN16934 P7C3 301353-96-8 P7C3 is a brain-penetrant NAMPT activator with proneurogenic and neuroprotective effect
CSN17999 Nampt-IN-1 1698878-14-6 Nampt-IN-1 is an inhibitor of NAMPT with IC50 of 18 nM NCI-H1155 cell 49 nM Calu-6 cell 333 nM HCC1937 cell and 389 nM MCF-7 cell respectively
CSN20325 NAMPT Inhibitor C52 2109805-79-8 NAMPT inhibitor C52 is a non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase NAMPT with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent antitumor activity when dosed orally in mouse xenograft models
CSN17752 GNE-617 1362154-70-8 GNE-617 is a potent NAMPT inhibitor with IC50 value of 5nM
CSN19050 GNE-617 HCl 2070014-99-0 GNE-617 hydrochloride is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer
CSN16223 GMX1778   200484-11-3 GMX1778 is a competitive NAMPT nicotinamide phosphoribosyltransferase inhibitor
CSN16330 FK866 658084-64-1 FK866 effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM in a cell-free assay.
CSN18096 CB-30865 206275-15-2 CB30865 is a potent inhibitor of NAMPT an enzyme present in the NAD biosynthetic pathway
CSN18183 CB-300919 289715-28-2 CB-300919 is a water-soluble analogue of CB30865 a potent inhibitor of nicotinamide phosphoribosyltransferase Nampt and has a continuous exposure96 h growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft
CSN20326 A-1293201 1375557-33-7 A-1293201 is a non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase NAMPT with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent antitumor activity when dosed orally in mouse xenograft models
<< PREV 1 NEXT >>